Japan· JP-6399404A5030
インターフェロンアルファ（ＮＡＭＡＬＷＡ）
A medicinal product containing インターフェロンアルファ（ｎａｍａｌｗａ）, registered in Japan by 住友ファーマ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- インターフェロンアルファ（ＮＡＭＡＬＷＡ）
- Manufacturer
- 住友ファーマ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
インターフェロンアルファ（ｎａｍａｌｗａ） in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Hungary · Egiferon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/84a1961d-53b3-48b4-b75f-4c5bd3df133e GET /v1/drugs/84a1961d-53b3-48b4-b75f-4c5bd3df133e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "３００万国際単位１筒",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "6399404A5030",
"category": "注射薬",
"price_yen": 25865,
"generic_name": "インターフェロンアルファ（ＮＡＭＡＬＷＡ）",
"product_name_jp": null,
"therapeutic_class": "6399",
"transitional_expiry": null
}See everything about インターフェロンアルファ（ｎａｍａｌｗａ）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.